WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Monday, March 7, 2016

A toxic byproduct of hemoglobin could provide treatments for Creutzfeldt-Jakob disease

March 7, 2016

Neena Singh, M.D., Ph.D.

Professor


Scientists at Case Western Reserve University School of Medicine have identified a novel mechanism that could be used to protect the brain from damage due to stroke and a variety of neurodegenerative conditions, including sporadic Creutzfeldt-Jakob disease, Alzheimer's disease, and Parkinson's disease. 
Neena Singh, MD, PhD, a professor of pathology at the school, has spent much of her career studying the role of metals such as iron, copper, and zinc in the pathology of neurodegenerative diseases. She has previously reported that some of these metals are regulated by the brain's normal prion protein, called PrPC. Her goal is to identify common pathogenic processes in neurodegenerative diseases that could lead to the development of a new generation of treatments. 
In her latest study, published in The Journal of Alzheimer's Disease, Singh and post-doctoral research fellow Ajai K. Tripathi, PhD, studied a byproduct of hemoglobin called hemin that is released from red blood cells during stroke and is toxic to neurons. Other scientists have reported that PrPC is upregulated in damaged tissue following stroke, and protects the tissue from further damage. 
It was this finding that got Singh and her group interested in how PrPC protects neurons from hemin-induced toxicity. In a series of elegant experiments, Singh said they found that hemin binds to PrPC on many diverse cell lines. What was surprising was that the interaction between hemin and PrPC actually up-regulated hemoglobin synthesis in hematopoietic and neuronal cells. "Neuronal hemoglobin may be endowed with similar biological functions that are found in red cells, and is likely to improve neuronal survival by supporting their metabolism," explained Singh. 
In addition, hemin and PrPC form a complex, resulting in the removal of hemin and reducing the amount of PrPC available for conversion to the PrP-scrapie form. The latter is responsible for scrapie in sheep and goats and Creutzfeldt-Jakob disease in humans. Treatment with hemin has been shown to delay the onset of scrapie in experimental models. This study suggests that in addition to reducing the generation of PrP-scrapie, hemin protects neurons by inducing hemoglobin synthesis. "The hemin-PrPC interaction therefore reveals a unique function of PrPC that is likely to impact the therapeutic management of cerebral hemorrhage and CJD."
This synergy may play a role in other brain diseases as well. Dr. Singh said that altered levels of neuronal hemoglobin have been reported in multiple sclerosis, Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies. "We think that manipulation of neuronal hemoglobin may provide an effective method of improving neuronal survival," said Dr. Singh. "Further studies are necessary to explore viable options that take advantage of PrPC and hemin in this process."
###
About Case Western Reserve University School of Medicine 
Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation's top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School's innovative and pioneering Western Reserve2 curriculum interweaves four themes -- research and scholarship, clinical mastery, leadership, and civic professionalism -- to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.
Annually, the School of Medicine trains more than 800 MD and MD/PhD students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News & World Report, "Guide to Graduate Education."
The School of Medicine's primary affiliate is University Hospitals Case Medical Center and is affiliated additionally with MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002. http://casemed.case.edu.
http://www.eurekalert.org/pub_releases/2016-03/cwru-atb030716.php

No comments:

Post a Comment